Mylan acquires rights to Apsen's Arixtra injection

PITTSBURGH — Mylan announced that its subsidiary, Mylan Ireland Limited, has agreed to acquire the U.S. rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic version of Arixtra from Aspen Global. The drug is used to prevent deep vein thrombosis. Mylan is currently selling the drug in the United States through an arrangement with Aspen. Apotex is selling generic Arixtra, which will be transitioning to Mylan by the end of the year, the company stated. 

 

"The addition of Arixtra is an attractive opportunity to broaden the range of therapeutic categories we market in the United States, in both the hospital and retail settings, and bolster our growing portfolio of complex injectables to better meet our customers' needs," said Heather Bresch, Mylan CEO. 

 

Mylan will pay Apsen $225 million once the transaction is complete, with an additional $75 million that will be held in escrow and released when certain conditions are met. Aspen will supply Arixtra and its generic equivalent to Mylan. 

 

Arixtra and the authorized generic had sales in the United States of $18.8 million and $95.3 million, respectively, for the 12 months ending June 30, 2014, according to IMS Health data.